^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Nasopharyngeal Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/08/2021
    Excerpt:
    SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS: Useful in Certain Circumstances...Pembrolizumab (for TMB-H tumors [>/=10 mut/Mb])
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Excerpt:
    KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.